Czy galektyna-3 ma związek z nerkowym wydalaniem albumin w cukrzycy typu 2?

Yücel, Nihal; Madenci, Özlem Çakır; Bölük, Aycan; Dağdelen, Lale Köroğlu; Temel, Yusuf; Sargın, Mehmet; Orçun, Asuman

doi:10.5603/ep.a2016.0036

Cited by 5 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tan et al as well revealed that serum galectin-3 levels were significantly correlated with age, eGFR, urine ACR, and HbA1c, but no correlation was seen with BMI, duration of diabetes, or SBP 24. Far from our results, Yücel et al concluded that no relation was between galectin-3 and the parameters of DM, such as duration of DM, HbA1c, or FPG 28…”

Section: Discussioncontrasting

confidence: 75%

“…In accordance with our results, a large cohort study performed by Tan et al showed that galectin-3 was independently associated with progression of DN (eg, macroalbuminuria), deterioration of renal function (eg, doubling of serum creatinine), as well as initiation of renal replacement therapy after a mean follow-up of 9 years 24. On the other hand, Yücel et al concluded that serum galectin-3 values had no relation to the levels of urinary albumin excretion in patients with DM 28…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Galectin-3 as a prognostic biomarker for diabetic nephropathy</p>

Hodeib¹,

Hagras²,

Watany³

et al. 2019

DMSO

View full text Add to dashboard Cite

Introduction: Diabetic nephropathy (DN) represents one of the main causes of end-stage renal disease in type 2 diabetes mellitus (DM) patients. Galectin-3 has been implicated in pathogenesis of many pathological conditions. To date, there are limited data regarding the relationship between galectin-3 and DN. Aim of the study: Evaluation of serum galectin-3 as a novel prognostic biomarker in patients with DN.

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

<p>Galectin-3 as a prognostic biomarker for diabetic nephropathy</p>

Hodeib¹,

Hagras²,

Watany³

et al. 2019

DMSO

View full text Add to dashboard Cite

show abstract

“…Since Gal-3 is a DN biomarker that is highly expressed in the serum 29,30 , we detected the expression of Gal-3 in DN in vivo and in vitro. Immunohistochemistry (Fig.…”

Section: Resultsmentioning

confidence: 99%

Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3

et al. 2019

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the most significant complications of diabetes and is the primary cause of end-stage kidney disease. Cumulating evidence has shown that renal inflammation plays a role in the development and progression of DN, but the exact cellular mechanisms are unclear. Irregular expression of long non-coding RNAs (lncRNAs) is present in many diseases, including DN. However, the relationship between lncRNAs and inflammation in DN is unclear. In this study, we identified differentially expressed lncRNAs in DN using RNA-sequencing. Among these lncRNAs, we identified seven DN-related lncRNAs in vivo and in vitro using quantitative real-time PCR. One lncRNA in particular, Rpph1 (ribonuclease P RNA component H1), exhibited significantly increased expression. Further, over-expression or knockdown of Rpph1 was found to regulate cell proliferation and the expression of inflammatory cytokines in mesangial cells (MCs). The results revealed that Rpph1 directly interacts with the DN-related factor galectin-3 (Gal-3). Further, over-expression of Rpph1 promoted inflammation and cell proliferation through the Gal-3/Mek/Erk signaling pathway in MCs under low glucose conditions, while knockdown of Rpph1 inhibited inflammation and cell proliferation through the Gal-3/Mek/Erk pathway in MCs under high glucose conditions. These results provide new insight into the association between Rpph1 and the Gal-3/Mek/Erk signaling pathway during DN progression.

show abstract